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1. Summary/Zusammenfassung 
1.1. Summary  
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the 
incidence is still increasing. The epithelial to mesenchymal transition (EMT) of malignant 
hepatocytes in HCC is considered as a major cause of liver cancer progression and metastasis.  
In this study we aimed to establish a human cellular model of HCC to investigate the 
molecular mechanisms of EMT and to examine the efficacy of anti-cancer agents in this 
process.Two liver cell lines were established from one HCC patient showing either an 
epithelial or mesenchymal phenotype. Immunofluorescence analysis confirmed the distinct 
epithelial and mesenchymal characteristics of HCC cells. Most remarkably, mesenchymal 
HCC cells showed enhanced migration and invasion in vitro. Comparative genomic 
hybridization and short tandem repeat analysis indicated a unique cellular origin of both cell 
types, suggesting that mesenchymal cells derived from epithelial hepatocytes via EMT in 
vivo. Loss of epithelial as well as gain of mesenchymal markers analyzed by whole genome 
expression profiling verified EMT. Interestingly, methylation-specific PCR analysis revealed 
epigenetic upregulation of secreted protein, acidic, rich in cystein (SPARC) in mesenchymal 
cells via promoter demethylation. Upon drug exposure, mesenchymal HCC cells showed a 
higher resistance to the targeted therapeutic agents sorafenib and erlotinib as compared to 
epithelial HCC cells, which were slightly more resistant to cytostatic drugs. Combination of 
doxorubicin and sorafenib caused an increased susceptibility of both cell lines to cytostatic 
effects resulting in an equalization of IC50 values, thus showing an effective treatment to 
target both, epithelial and mesenchymal cells.  
In conclusion, we established a unique EMT model of human HCC for pre-clinical studies 
which allows studying drug efficacy during HCC progression including the assessment of 
synergistic anti-cancer drug profiles.  
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1.2. Zusammenfassung 
Das hepatozelluläre Karzinom ist die sechst häufigste Krebserkrankung weltweit, dessen 
Inzidenz nach wie vor steigend ist. Die epitheliale zur mesenchymalen Transition (EMT), ein 
Prozess bei dem epitheliale Zellen ihre typische Organisation verlieren und dadurch in das 
umliegende Gewebe invadieren können, wurde als eine Hauptursache der fortschreitenden 
Leberkrebserkrankung und deren Metastasierung  identifiziert.  
Ziel dieser experimentellen Studie war, ein humanes zelluläres Modell der EMT zu 
entwickeln, um einerseits molekulare Mechanismen der EMT zu identifizieren und 
andererseits die Effizienz antitumoraler Medikamente in diesem Prozess zu untersuchen. 
Dafür wurden zwei Leber-Zelllinien, welche einen epithelialen beziehungsweise einen  
mesenchymalen Phänotyp aufweisen, aus dem Tumor eines HCC Patienten isoliert. Die 
Immunfluoreszenzanalyse bestätigte die epithelialen und mesenchymalen Charakteristika 
dieser HCC Zelllinien. Weiters konnten wir zeigen, dass die mesenchymalen HCC Zellen, im 
Vergleich zu den epithelialen, eine höhere Migration und Invasion in vitro aufweisen. Die 
chromosomale Analyse mittels vergleichender genomischen Hybridisierung und eine ‘Short 
Tandem Repeat‘ Analyse bestätigten, dass beide Zelltypen ursprünglich aus einer Zelle 
entstanden sind. Dies zeigt damit eindeutig, dass sich die mesenchymalen Zellen durch eine 
EMT in vivo aus den epithelialen Zellen entwickelt haben. Durch die Expressionsanalyse des 
gesamten Transkriptoms konnte der Verlust von epithelialen und der Erwerb von 
mesenchymalen Markern nachgewiesen werden, wodurch eine EMT bestätigt wurde. Eine 
methylierungsspezifische Polymerase- Kettenreaktion (PCR) ergab weiters, dass das Protein 
‘Secreted Protein, Acidic, Rich in Cystein‘ (SPARC), das in den mesenchymalen HCC Zellen 
stark überexprimiert ist, durch Demethylierung seines Promotors epigenetisch reguliert wird.  
Ebenso konnten wir zeigen, dass mesenchymale HCC Zellen im Vergleich zu den epithelialen 
HCC Zellen eine höhere Resistenz gegen zielgerichte Therapien wie Sorafenib und Erlotinib 
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aufweisen, wohingegen epitheliale HCC Zellen stärker resistent gegen zytostatische 
Medikamente sind. Die Kombination von Doxorubicin und Sorafenib verursacht eine erhöhte 
Empfindlichkeit von beiden Zelllinien, was dazu führt, dass sich die maximalen mittleren 
inhibitorischen Konzentrationen (IC50) einander angleichen. Diese Kombination ist folglich 
eine effiziente Behandlung um beide, eptiheliale als auch mesenchymale Hepatomzellen 
erfolgreich zu eliminieren.  
Zusammenfassend konnten wir ein einzigartiges EMT Modell des humanen HCCs 
entwickeln, das in präklinischen Studien eingesetzt werden kann, um (i) die cytostatische 
Effizienz einer Substanz in vitro zu testen, (ii) ein Profil des Wirkstoffs mit dessen 
Auswirkung auf zelluläre Mechanismen zu erstellen und (iii) Synergismen mit weiteren 
Antikrebsmitteln zu identifizieren.  
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2. Introduction 
2.1. Hepatocellular carcinoma - HCC 
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide (Parkin et al., 
2005) and the incidence is still increasing in Europe and the United States (El-Serag and 
Mason, 1999). The survival rates are 3% to 5% in the US and developing countries due to its 
very poor prognosis. Therefore, HCC  is categorized as the third most common cause of death 
from cancer (Parkin et al., 2005). HCC has well defined major risk factors  including 
infections with hepatitis B or C (HBV or HCV), Aflatoxin B1 intoxication, and chronic 
alcohol abuse (El-Serag and Mason, 1999). The incidence of HCC varies geographically, 
corresponding to the distribution of risk factors worldwide. For example, HBV infection and 
Aflatoxin B1 intoxication from contaminated food are common in Asia and Africa. In 
contrast, the main risk factors in the Western World and Japan are HCV infections as well as 
alcohol abuse (El-Serag and Rudolph, 2007). These multiple factors contributing to HCC 
development might explain the complex molecular pathogenesis of this disease (Thorgeirsson 
and Grisham, 2002).  
 
Development of HCC 
Hepatocaricinogenesis is a multifactorial and multistep process that involves various genetic 
and epigenetic changes which finally lead to malignant transformation of hepatocytes (Blum 
and Spangenberg, 2007). 80% of all HCC cases develop from cirrhotic livers. This continuous 
damage and regeneration of hepatocytes in a context of inflammation, immune response or 
oxidative DNA damage leads to the development of hyperplastic nodules (Blum and 
Spangenberg, 2007), which represent a potential first step towards HCC (Figure 1). These 
lesions can progress to pre-malignant dysplastic nodules, surrounded by connective tissue.  
Finally, dysplastic nodules can evolve into HCC by addition of other genetic or epigenetic 
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changes. HCC can be classified into well, moderately or poor differentiated tumors, of which 
the latter represents the most malignant form of primary HCC (Figure 1; Farazi and DePinho, 
2006). Further progression of the disease leads to vascular invasion which subsequently leads 
to intrahepatic dissemination of cancer cells. In advanced stages of HCC, tumor cells can 
invade into larger vessels, mostly into portal veins and finally circulate systemically through 
the blood stream and metastasize into distant organs (Schwartz et al., 2007). 
 
 
Figure 1. Pathogenesis of hepatocellular carcinoma (Farazi and DePinho, 2006). Continuous 
hepatic necrosis and regeneration in chronic liver disease leads to the development of abnormal liver 
nodules in a cirrhotic background. Pre-malignant hyperplastic nodules with increased genomic 
instability evolve into dysplastic cells, which can develop HCC after further genetic or epigenetic 
changes.  
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Molecular mechanisms of HCC 
Several key mechanisms are involved in tumor formation and can be classified in six 
functional groups including self- sufficiency in growth signals, insensitivity to anti-growth 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and tumor 
invasion and metastasis (Figure 2; Hanahan and Weinberg, 2000).  
 
 
Figure 2. Acquired functions of cancer cells (Hanahan and Weinberg, 2000). During cancer 
development, most cancer cells gain a set of functional capabilities.  
 
 
The genetic aberrations and signaling pathways involved in hepatocarcinogenesis are mostly 
depending on the various etiologies, but there are some common molecular changes in HCC 
development (Aravalli et al., 2008; Farazi and DePinho, 2006): 
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1. Genetic aberrations: Overall, telomerase activity was found to be increased in the majority 
of HCCs  (Farazi et al., 2003). Several other genes were found to be frequently related to 
hepatocarcinogenesis of which the overexpression of c-myc and CCND1/Cyclin D1 as 
well as the mutation or deletion of tumor suppressor such as AXIN1, p53, CDH1/E- 
cadherin or PTEN are the most common ones (Minguez et al., 2009).  
2. Wnt/β-catenin pathway: This pathway was shown to be the most common disrupted 
pathway in HCC. It is involved in HCC arising from virus-infections and alcoholic liver 
cirrhosis (Aravalli et al., 2008). Mutations in β-catenin or AXIN1, epigenetic silencing of 
E-cadherin or aberrant expression of Wnt/frizzeled receptors are the most causes for the 
activation of the Wnt/β-catenin pathway, which leads to the translocation of membrane-
bound β-catenin into the nucleus where it acts as a transcriptional regulator of oncogenes 
such as c-myc and cyclin D1 (Minguez et al., 2009). 
3. p53 pathway: The tumor suppressor gene TP53 is inactivated in about half of all human 
tumors and in about 30%- 60% of HCC patients (Cha and Dematteo, 2005; Minguez et 
al., 2009). Under physiological conditions, p53 suppresses cell replication and induces 
apoptosis (Kern et al., 1992). The loss of p53 leads to an uncontrolled expansion of 
hepatocytes, chromosomal instability and initiation of HCC (El-Serag and Rudolph, 
2007). Indeed, mutations in the TP53 were found to be associated with a higher 
chromosomal instability, poor differentiated tumors and poor prognosis of patients (Honda 
et al., 1998; Laurent-Puig et al., 2001). The p53 pathway can be affected at different 
levels in human HCC. Beside mutations in the p53 gene, microdeletions of p14ARF occur 
in 15%-20% of human HCC and overexpression of Mdm2 as well as Gankyrin, which 
inhibits the Retinoblastoma (Rb) - and p53- checkpoints, were observed in human HCCs 
(El-Serag and Rudolph, 2007).   
4. The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of Rapamycin (mTOR) 
pathway is activated in 30-50% of all HCCs. It can be upregulated via abnormal activation 
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of tyrosine kinase receptors, including epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor receptor (VEGFR), or platelet derived growth factor receptor 
(PDGFR). Alternatively, the loss of the tumor suppressor gene PTEN leads to the 
constitutive activation of PI3K (Villanueva et al., 2008). 
5. The Ras/Raf/Erk pathway is activated in nearly all advanced stages of liver cancer, mostly 
as a result of increased upstream signaling by epidermal growth factor (EGF), hepatocyte 
growth factor (HGF) or insuline like growth factor (IGF) (Calvisi et al., 2006).  
6. ErbB receptors belong to the receptor tyrosine kinase family and all four members 
(ERBB1-ERBB4) are found to be overexpressed in HCC. ERBB1, also kown as EGFR, 
and ERBB3 expression were found to correlate with higher aggressiveness of HCC 
(Farazi and DePinho, 2006; Ito et al., 2001). 
7. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is 
known to play an important role in angiogenesis. HCC is a highly vascularized tumor, and 
angiogenesis plays an important role in its development and progression. On the one hand 
VEGF stimulates cell proliferation and thus, budding of new blood vessels around the 
growing tumor. On the other hand it facilitates cell migration during invasion via 
promotion of fibrin scaffolding (Kaseb et al., 2009). VEGF was shown to be expressed in 
63% of encapsulated, 78% of nonencapsulated HCCs and in 90% of HCCs with 
extrahepatic metastasis (Yao et al., 2005). Another study showed a correlation of VEGF 
expression with vascular invasion, intrahepatic metastasis and shorter overall survival in 
HCC patients (Deli et al., 2005).  
8. The transforming growth factor beta (TGF-β) plays an important role in the suppression of 
hepatocyte proliferation under physiological conditions. However, its misregulation can 
result in tumorigenesis by promotion of cell invasion, downregulation of immune 
responses and modifications of the microenvironment (Massague, 2008). HCCs 
expressing late TGF-β responsive genes (anti-apoptotic and metastatic) demonstrate a 
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higher invasive phenotype and increased tumor recurrence compared to those showing an 
early TGF-β signature (tumor suppressive) (Coulouarn et al., 2008). 
 
Involvement of microRNAs in hepatocarcinogenesis 
Different classes of noncoding RNAs have been found in mammalian cells, including small 
interfering RNAs (siRNA), small nucleolar RNAs (snRNA) and micro RNAs (miRNAs) 
(Aravalli et al., 2008). miRNAs regulate the expression of their target mRNAs on a post-
transcriptional level (Minguez et al., 2009). The currently best known miRNA in the liver is 
miR-122, which was shown to target Cyclin G1 and to be associated with a poor prognosis in 
human HCC (Coulouarn et al., 2009). MiR-21, which downregulates the expression of the 
tumor suppressor PTEN, was shown to be upregulated in HCC compared to nontumoral tissue 
(Meng et al., 2007). Many other studies identified various deregulated miRNAs in HCC, i.e. 
the expression of miR-26 was found to be associated with poor prognosis in human HCC (Ji 
et al., 2009). HCCs may have a distinct miRNA fingerprint according to risk factors, genetic 
alterations and malignancy of the tumor. Finding these relationships may provide new insights 
into miRNA deregulation in carcinogenesis. Thus, they may be promising  diagnostic markers 
in hepatocarcinogenesis (Imbeaud et al., 2010).  
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2.2. Classification of HCC 
Molecular classification of HCC 
In the past decades many studies on expression profiles of HCC were performed and different 
investigators tried to classify HCC based on its molecular expression signature. One recent 
study revealed by integration of genomic and molecular alterations five distinct classes of 
HCC (Chiang et al., 2008). One is associated with mutations in β-catenin, indicating that 
alterations in the canonical Wnt signalling are involved. Another subtype revealed increased 
proliferation, chromosomal instability and showed a high phosphorlylation rate of insulin-like 
growth factor 1 receptor (IGF-1R), ribosomal protein (RP)S6 and Akt. Another distinct 
subgroup showed an upregulation of interferon (IFN) stimulated genes, including signal 
transducer and activator of transcription (STAT) 1. Furthermore, a newly defined subclass 
showed a strong association with polysomy of chromosome 7. 
Another recent study, a meta-analysis of 9 different transcriptome-analyses revealed three 
distinct molecular subclasses of HCC (Figure 3; Hoshida et al., 2009). The subclass S1 is 
associated with an invasive phenotype, poor survival of patients and activated Wnt- and TGF-
β gene expression signature. The S2 subclass comprises tumors with a MYC and AKT 
activated signature and also correlates with poor survival. Subclass S3 tumors showed a 
hepatocyte-related gene expression and are associated with good survival of patients (Hoshida 
et al., 2009). 
These analyses may help to define a robust molecular classification of HCC (Imbeaud et al.), 
to identify new biomarkers for early detection of tumor progression and to unravel new 
targets for therapies (Chiang et al., 2008).  
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Figure 3.  Molecular classification of HCC (Hoshida et al., 2009). Subclasses S1, S2 and S3 show 
distinct molecular characteristics. 
 
Clinical classification of HCC  
In the management of HCC, a classification system is an important component to determine 
subgroups of patients and to supply them with reasonable treatment (Llovet et al., 2003). 
Various classification systems are available for HCC, of which one of the most popular ones 
is the Tumor-Node-Metastasis (TNM) classification. According to the International Union 
against cancer (UICC), the TNM staging is based on the size of tumor (T), the status of lymph 
nodes near the tumor (N) and the presence of metastasis (M) (Thiery, 2002). However, it was 
found that this system may not be very helpful for prognosis because it does not evaluate the 
underlying liver disease, which is a major cause of mortality in patients with HCC (Schafer 
and Sorrell, 1999). 
In the last years the Barcelona Clinic Liver cancer classification (BCLC) has emerged as a 
standard classification (Llovet et al., 2003). It was presented for the first time in the journal 
‘Seminars in Liver disease’ in 1999 (Llovet et al., 1999). The main prognostic factors of this 
staging system are related to the tumor status (number and size of nodules, vascular invasion, 
extrahepatic spread), the liver function (defined by the Child Pugh score system, serum 
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bilirubin, serum albumin, portal hypertension) and general health status (defined by the 
Eastern Cooperative Oncology group [ECOG]) (Llovet et al., 2008a). The current BCLC 
categories and the corresponding therapeutic strategies are shown in Figure 4.  
A very early stage (stage 0) is defined as a single HCC nodule with a diameter of ≤ 2cm 
employing a normal liver function and diagnosed as carcinoma in situ. These patients are 
optimal candidates for resection and show a 5 year survival rate of 90% after treatment 
(Forner et al., 2010).  
Early stage HCC (stage A) classification is determined by one to three nodules with a 
diameter of < 3 cm. The liver function is defined by Child Pugh A or Child Pugh B status. 
Dependent on their liver function and tumor size, patients should be considered for radical 
therapy like resection, liver transplantation or local ablation via percutaneous ethanol 
injection (PEI) or radiofrequency ablation (RF) (Forner et al., 2010; Greten et al., 2005; 
Llovet and Bruix, 2003). 
Intermediate stage HCC (stage B) is characterized by a preserved liver function with a large 
or multifocal tumor, no vascular invasion or extrahepatic spread and the absence of 
symptoms. Untreated patients suffering from intermediate stage HCC have a median survival 
of approximately 16 months (Llovet and Bruix, 2003). These patients can benefit from 
transarterial chemoembolisation (TACE) (Bruix and Llovet, 2009), which results in a median 
outcome of  20 months (Forner et al., 2010). 
In advanced stage HCC (stage C), vascular invasion or extrahepatic spread is detected and the 
patients suffer already from disease-related symptoms. The median survival is about 7 months 
and the outcome is mostly depending on the liver function. It was found that the multitarget 
tyrosine kinase inhibitor sorafenib improves survival of advanced stage HCC patients. The 
median overall survival was 10.7 months for sorafenib vs 7.9 months for placebo (Zhang et 
al., 2010).  
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End stage (stage D) HCC includes those patients with a high tumor burden associated with an 
ECOG performance status of 3 or 4. These patients have a median survival of 3 months and 
only palliative therapies are possible (Llovet et al., 2003). 
 
 
Figure 4. Barcelona Clinic liver cancer staging and treatment recommendation (Forner et al., 
2010). HCC patients can be grouped into five stages depending on tumor burden, liver function and 
physical status: very early (0), early (A), intermediate (B), advanced (C) and end (D) stage HCC. 
Staging is further connected to the recommended treatment option. CLT, cadaveric liver 
transplantation; LDLT, living donor liver transplantation; PEI, percutaneus ethanol injection; RF, 
radiofrequency ablation. 
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2.3. Treatment of HCC 
Only 30-40% of all HCC patients are eligible for curative treatments (Llovet et al., 2003). In  
those patients, resection and liver transplantation result in 5-year survival rates of 70% and 
local ablation therapies reach about 50% (Llovet et al., 2003). Because many patients are not 
eligible for resection,  therapy of unresectable HCC has been under extensive research in the 
past decades (Llovet and Bruix, 2003). HCC develops mostly in the setting of cirrhosis 
involving impaired liver function. The liver is the main organ for metabolism and cirrhosis 
decreases the activity of drug metabolizing enzymes and alters the absorption, plasma protein 
binding, distribution, and renal excretion of drugs (Thomas and Abbruzzese, 2005).  
For unresectable HCC, treatment options depend mostly on the stage of the disease. 50% of 
HCC patients are diagnosed at an intermediate to advanced stage (Greten et al., 2005) due to 
the lack of symptoms during early stages and the rapid progression of the disease (Sun and 
Sarna, 2008). Patients with intermediate stage HCC can benefit from transarterial 
embolisation (TAE)/TACE.  
The blood supply of healthy liver is covered by 85% from the portal vein and only 5% from 
the hepatic artery. In contrast, in HCC the blood mainly originates from the hepatic artery, 
thus TAE/TACE is one therapy of choice. TAE induces the obstruction of the hepatic artery 
using embolising agents such as an absorbable gelatine sponge, or alcohol, to induce tumor 
necrosis. During TACE, chemotherapeutic agents get injected into the artery and subsequently 
arterial obstruction is performed. With this method it is possible to use high drug doses which 
is constricted specifically to the tumor area and thus, systemic toxicity can be minimized 
(Rampone et al., 2009). A meta – analysis of several studies showed, that chemoembolization 
with doxorubicin or cisplatin improves survival of patients with unresectable HCC (Llovet 
and Bruix, 2003). One of the recent achievement was the development of drug eluting beads 
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(DEB) which induce arterial obstruction and  release simultaneously a chemotherapeutic drug 
such as doxorubicin  (Forner and Trinchet, 2009; Varela et al., 2007). 
In advanced stages of HCC, curative therapies are no longer possible. Because of the 
advanced stage of cirrhosis and reduced liver function also systemic treatment is a major 
challenge and thus was under extensive research (Schwartz et al., 2007). The finding that 
estrogens may promote liver tumor growth  (Francavilla et al., 1989) has led many 
investigators to test hormonal therapy. Tamoxifen, an antiestrogenic compound, was tested in 
several studies but it failed to improve survival in patients with advanced HCC (Zhu, 2006). 
Other hormonal therapies like anti-androgens or octreotide, a somatostatine analogue, showed 
also no benefit (Lopez et al., 2006). Systemic treatment with doxorubicin, the most widely 
used agent in HCC, was tested but the outcomes remain almost inconclusive (Zhu, 2006). 
Chemotherapeutics such as epirubicin, cisplatin, 5-fluoruracil or the combination of cisplatin, 
interferon alpha, doxorubicin and 5-fluoruracil (PIAF) have failed to demonstrate a significant 
acitivtiy (Zhu, 2006). Other compounds like noatrexed, a thymidilate synthase inhibitor, 
seocalocitol, a vitamin D-like antiproliferative molecule, or a tubulin inhibitor (T-67) also 
showed no benefits in treatment of HCC in randomized controlled trials (RCTs) (Llovet and 
Bruix, 2008). 
With the improvement in understanding the molecular mechanisms of hepatocarcinogenesis, 
new molecular targeted agents have been developed. Recently it was shown that sorafenib, 
which targets Raf-1, B-Raf, VEGFR1&2 and PDGFR improves survival of patients with 
advanced HCC (Cheng et al., 2009; Llovet et al., 2008b; Wilhelm et al., 2006). This was a 
major breakthrough in treatment of advanced HCC and gives the rationale to develop further 
molecular targeted therapies against this otherwise rather chemoresistant tumor. Several 
molecular therapies have been tested in pre-clinical studies and clinical trials. They can be 
summarized in 4 different groups of targets (Figure 5; Llovet and Bruix, 2008). 
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1. Inhibitors of EGFR: erlotinib, gefitinib, lapatinib, cetuximab. Only erlotinib showed an 
activity in pre-clinical and clinical studies, whereas the efficacies of the other compounds 
showed inconclusive results and thus remain to be further elucidated (Llovet and Bruix, 
2008). 
2. Inhibitors of angiogenic factors: humanized monoclonal antibodies such as bevacizumab 
and small molecules such as sorafenib, sunitinib, brivanib. HCC are mostly highly 
vascularized tumors and it was shown that VEGF, PDGF and angiopoeitin are often 
upreguated in this disease  (Farazi and DePinho, 2006). Bevacizumab, an antibody against 
VEGF in combination with erlotinib was shown to have an antitumoral activity (Thomas 
et al., 2009). Sunitinib was compared in a phase III randomized study to sorafenib, but 
although they have similar targets,  sunitinib shows more toxic effects (Zhu et al., 2009) 
and the study had to be terminated (Clinicaltrials.gov NCT00699374). The data from 
some first line treatments of HCC with brivanib seem to be promising and a phase III 
study is ongoing (NCT00858871) (Finn, 2010)  
3. Inhibitors of PI3K/Akt/mTOR: everolimus and temsirolimus. About 50% of HCC patients 
have an activation of the mTOR pathway (Villanueva et al., 2008). Preclinical in vitro 
data showed that mTOR inhibition by rapamycin and analogues reduces HCC growth and 
improves survival (Sahin et al., 2004). Phase II studies are currently testing analoges of 
rapamycin including everolimus and temsirolimus alone or in combination with sorafenib 
(Llovet and Bruix, 2008). 
4. Inhibitors of c-met, IGFR1 and Wnt. The Wnt pathway is activated in 33% to 67% of 
HCCs (Lee et al., 2006a). At the moment there are no drugs available that can block its 
activation without causing significant side effects. Other studies with inhibitors against 
IGFR1 or c-Met are ongoing (Llovet and Bruix, 2008).  
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Figure 5. Key pathways in hepatocarcinogenesis and molecular targeted therapies currently 
used in preclinical or clinical trials (Llovet and Bruix, 2008). Monoclonal antibodies against VEGF 
(Bevacizumab) and EGFR (cetuximab), tyrosine kinase inhibitors against VEGFR (sorafenib, 
sunitinib), PDGFR (sorafenib, sunitinib), EGFR (erlotinib, lapatinib, AEE788) and Her2/neu 
(lapatinib, AEE788); tyrosine kinase inhibitors against Raf (sorafenib) mTOR (rapamycin, 
everolimus) and PI3K (XL-765)  
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2.4. Epithelial to mesenchymal transition - EMT 
Epithelial to mesenchymal transition is described as a process where epithelial cells lose their 
polarization and cell-cell contacts by concomitant acquisition of a mesenchymal gene 
expression associated with increased motility (Figure 6). Epithelial cells are organized in 
layers and form basolateral adherens junctions composed of E-cadherin, catenins and actin-
rings along with desmosomes as well as tight junctions, which represent apical polarity 
complexes. Integrins anchor the cells to the extracellular matrix via hemidesmosoms and focal 
adhesions. During EMT cells loose both, adherence and tight junctions, leading to the loss of 
the cell polarity and gain of mesenchymal and migratory traits. Cytoskeletal rearrangement by 
actin stress fibre formation and expression of matrix metalloproteinases favors cellular 
migration and invasion  (Acloque et al., 2009). 
 
Figure 6.  Process of EMT (Kalluri, 2009). EMT is a functional transition of polarized epithelial 
cells with adherence and tight junctions into mobile mesenchymal cells. Common EMT markers for 
epithelial and mesenchymal cells are listed. ZO-1, zonula occludens 1; MUC1, Mucin 1; cell surface 
associated, miR200, microRNA 200; FSP-1, fibroblast specific protein 1; SIP1, survival of motor 
neuron protein interacting protein 1; FOXC2, forkhead box C2. 
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On physiological conditions, EMT is crucial for an appropriate embryonic development. 
Epithelial cells show a high plasticity and can switch from an epithelial to an mesenchymal 
status and vice versa using the opposite process named mesenchymal to epithelial transition 
(MET; Thiery, 2002). In adults EMT occurs during wound healing, tissue regeneration and 
organ fibrosis to generate repair-associated mesenchymal cells. Furthermore, EMT is also 
involved in cancer progression, where it enables epithelial cancer cells to move locally and 
systemically into tumor surrounding tissues (Kalluri, 2009). Beside invasive and metastatic 
events in cancer progression, EMT participates also in other events that may be involved in 
tumor progression, including resistance to cell death and senescence, resistance to 
chemotherapy and immunotherapy as well as immune surveillance, immune suppression and 
inflammation (Thiery et al., 2009).  
All in all, EMT can be grouped in 3 different subtypes (Figure 7; Kalluri and Weinberg, 
2009). Type 1 EMT is involved in implantation, embryo formation, organ development and 
generates mesenchymal cells to create new tissues with specific functions. Fibrosis or 
uncontrolled cell-invasion are absent in this type. Type 2 EMT is associated with wound 
healing, tissue regeneration and organ fibrosis. In this context EMT is a part of a repair 
mechanism in which fibroblasts are generated to reconstitute and repair tissues after injury or 
inflammation. When an inflammation remains chronically, however, type 2 EMT can lead to 
organ fibrosis and finally to destruction of the organ  (Kalluri and Weinberg, 2009). The third 
proposed subtype is EMT type 3, which was shown to be associated with cancer progression 
and metastasis. This type occurs in epithelial cells that show already genetic or epigenetic 
changes, i.e. mutations in oncogenes or tumor suppressor genes. During type 3 EMT, cancer 
cells acquire migratory, invasive and metastatic properties (Kalluri and Weinberg, 2009).  
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Figure 7. Different subtypes of EMT (Kalluri and Weinberg, 2009). (A) Type 1 EMT is associated 
with gastrulation in embryonic development. The primitive epithelium develops via EMT to the 
primary mesenchyme, which subsequently can form the secondary epithelia by MET. (B) Type 2 EMT 
give rise to fibroblasts which are involved in repair mechanisms of inflammation and fibrosis, whereas 
(C) type 3 EMT is involved in cancer progression and enable cells to invade and metastasize. 
 
Molecular mechanisms of EMT 
The expression of E-cadherin in adherence junctions is essential for the maintenance of the 
epithelial phenotype in tissues. Downregulation of E-cadherin has been shown to play a 
crucial role in EMT during development and tumorigenesis. It leads to a loss of  cell-cell 
contacts, followed by the loss of cell polarity and further the translocation of β-catenin into 
the nucleus where it acts as a transcriptional activator of different oncogenes (Thiery, 2002). 
Different transcription factors were identified to be direct or indirect repressors of E-cadherin 
transcription, including Snail (Batlle et al., 2000), the basic helix-loop-helix (bHLH) 
transcription factors E47 and Twist, the Zinc finger E-box binding homeobox (ZEB) factors 
deltaEF1/ZEB1 as well as mothers against Decapentaplegic (Smad) interacting protein 
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(Sip)1/Zeb2  (Peinado et al., 2007). Once expressed and activated, each of the transcription 
factors activate different intracellular singaling cascades involving ERK, MAPK, PI3K, Akt, 
Smads, RhoB, β-catenin lymphoid enhancer binding factor (LEF), Ras, c-Fos as well as 
β4integrins and α5integrin (Tse and Kalluri, 2007). In case of many carcinomas, EMT-
inducing transcription factors can be activated by signals from the tumor associated stroma, 
particularly by HGF, EGF, PDGF and TGF-β (Kalluri and Weinberg, 2009; Thiery, 2002). 
Especially important among these regulators is TGF-β, which has an ambivalent role. On the 
one hand, TGF-β is an important suppressor of cell proliferation and helps to maintain tissue 
homeostasis. On the other hand, it can act also as a positive modulator of tumor progression 
and metastasis (Bierie and Moses, 2006). In this context, TGF-β can induce EMT through 
multiple mechanisms, including Smad signaling leading to differential expression of 
transcription factors and kinases and induce an autocrine TGF-β loop. Serveral studies 
showed that β-Catenin and LEF as well as PDGF cooperate with Smads, suggesting an 
important role of a TGF-β/Smad/LEF/PDGF axis in induction of EMT (Kalluri and 
Weinberg, 2009). Another mechanism is the phosphorylation of partitioning defective protein 
6 (PAR6A), which leads to the loss of cell polarity and loss of thight junctions (Ozdamar et 
al., 2005). Recently, it was shown that TGF-β is a potent inducer of Snail expression, which is 
known to mediate resistance to apoptosis (Barrallo-Gimeno and Nieto, 2005). Beside 
autocrine factors, other pathways including the Wnt/β-catenin-, Notch- and Hedegog 
signaling have a major impact on EMT during development and cancer progression (Huber et 
al., 2005). 
Beside loosing epithelial traits, many studies showed that carcinoma cells express 
mesenchymal markers such as alpha smooth muscle actin (α-SMA), fibroblast specific protein 
(FSP)1, vimentin and desmin during the EMT process (Yang and Weinberg, 2008). These 
cells are mostly located at the invasive front of primary tumors and are prone to invade and 
metastasise. The invasion-metastasis cascade consists of multiple essential steps, including 
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invasion into the surrounding tissue, breaking through the basal membrane, intravasation into 
the lymph or the blood vessels, systemic dissemination and finally extravasation and 
colonization at a distant site of a competent organ via the MET-process (Figure 7; Fidler and 
Poste, 2008; Thiery, 2002). 
 
 
Figure 7. Steps in tumor progression (Thiery, 2002). After tumor initiation, a normal epithelium 
develops into an adenoma. Tumor promotion including genetic and epigenetic changes can further 
lead to the EMT process which is necessary for breaking through the basal membrane and subsequent 
intravasation and systemic spread. Extravasation and the MET process are essential for the 
development of distant metastases.  
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2.5. EMT in HCC 
Several studies showed the occurrence of EMT during HCC development. Disruption of 
membrane-bound E-cadherin and β-catenin, the most important markers of EMT, were shown 
in 60,2% and 51,1% of primary HCC samples, respectively. The major regulators of EMT, 
Snail, Twist or Slug were identified in 43% to 56% of primary HCCs. HCC cell lines with 
increased Snail or Twist expression showed a higher invasive potential compared to cells with 
low Twist/Snail expression (Yang et al., 2009). In line with that,  Twist expression was found 
to correlate with HCC metastasis (Lee et al., 2006b). In murine hepatocytes TGF-β was 
shown to induce EMT via disorganization of the epithelial cell membrane, downregulation of 
cytoskeletal proteins and upregulation of mesenchymal and invasive markers (Cicchini et al., 
2008). It was shown that Ha-Ras transformed murine hepatocytes convert from an epithelial 
to a fibroblastoid phenotype upon TGF-β1 treatment and regulate their TGFβ signaling in an 
autocrine fashion (Gotzmann et al., 2002). These cells exhibited an accumulation of nuclear 
β-Catenin upon TGF-β treatment which has been even correlated with tumor recurrence in 
human HCC (Zulehner et al., 2009).  
In the past decades many novel factors which seem to play an important role in HCC 
progression were identified. In human HCC, blocking of TGF-βRI leads to increased 
expression of E-cadherin in the tumor and inhibits the synthesis of connective tissue growth 
factor (CTGF), produced by invasive tumor cells. This leads to diminished tumor growth, 
intravasation and metastatic dissemination of HCC cells (Mazzocca et al., 2010; Mazzocca et 
al., 2009). Furthermore, it was shown that TGF-β1 induces in cooperation with Laminin-5 
(Ln-5) an EMT resulting in a higher invasiveness of HCC cells (Giannelli et al., 2005). 
Another study showed that chromodomain helicase/ATPase DNA binding protein 1- like gene 
(CHD1L) induces EMT and increased cell motility through the Rho guanine nucleotide 
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exchange factor (ARHGEF)9 mediated activation of Cdc42 (Chen et al., 2010). Furthermore, 
eukaryotic Initiation factor (EIF5A2) can induce EMT in HCC (Tang et al., 2010).  
Taken together, a multitude of studies showed the importance of EMT in HCC progression 
and the correlation with higher invasion and tumor recurrence. Thus, it is of a particular 
importance to investigate the molecular mechanisms underlying EMT in HCC progression in 
order to identify key regulators which can be used as novel targets for further development of 
promising anti cancer strategies.  
 
2.6. Aim of the study 
EMT is a crucial event in HCC progression and recurrence. Until now there is no available 
human cellular model for EMT in HCC. Yet, such a model will be highly useful to identify 
novel targets for therapy and to test novel anti-cancer agents. Thus, the primary aim of this 
study was to establish a cellular model of EMT which faithfully reflects HCC progression. 
With this model we aimed on the one hand to examine the efficacy and specificity of 
chemotherapeutics and targeted therapeutic drugs currently used in clinics either alone or in 
synergistic action. On the other hand, we aimed to identify new key regulators of EMT which 
may be potent targets for future therapy of HCC.  
Data regarding the establishment of an unique human EMT model of HCC progression has 
been summarized in a manuscript which has already been submitted to a high-ranked 
scientific journal. 
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3.1. Abstract 
Background & Aims: The epithelial to mesenchymal transition (EMT) of malignant 
hepatocytes is a crucial event in hepatocellular carcinoma (HCC) progression and recurrence. 
We aimed to establish an EMT model of human HCC to examine drug efficacy and 
specificity in HCC progression. 
Methods: Two liver cell lines were established from one HCC patient showing either an 
epithelial or mesenchymal phenotype. HCC cell populations were characterized by 
immunofluorescence analysis, migration and invasion assays, comparative genomic 
hybridization (CGH), whole-genome expression profiling and promoter methylation. 
Therapeutic agents clinically used against HCC were examined for efficacy by determination 
of IC50 values. 
Results: Isolated HCC cells displayed an epithelial and a mesenchymal phenotype of which 
latter showed strong migratory and invasive abilities in vitro. CGH analysis indicated a 
common cellular origin of both cell types, suggesting that mesenchymal HCC cells have been 
derived from epithelial hepatocytes through EMT in vivo. Whole-genome expression profiling 
showed loss of epithelial as well as gain of mesenchymal markers, verifying EMT. Drug 
exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic 
agents sorafenib and erlotinib as compared to epithelial HCC cells, which were slightly more 
resistant to cytostatic drugs. Most remarkably, combined treatment of doxorubicin and 
sorafenib caused increased susceptibility of both HCC cell types resulting in enhanced drug 
efficacy by lowered IC50 values. 
Conclusion: The unique EMT model of human HCC allows the identification of molecular 
mechanisms and pre-clinical studies to assess therapeutic drug effectiveness during liver 
cancer progression. 
Key words: hepatocellular carcinoma; epithelial to mesenchymal transition; drug efficacy. 
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3.2. Introduction 
The epithelial to mesenchymal transition (EMT) enables carcinoma cells to invade into 
surrounding tissues and to form secondary tumors known as metastases. A particular 
characteristic of EMT is the downregulation of E-cadherin expression, which causes 
disruption of cell-cell junctions and dissemination of cells from the primary tumor [1]. 
Dysregulation of E-cadherin is provoked by its transcriptional repressors involving 
Snail/SNAI1, Slug/SNAI2, ZEB1/∆EF1, ZEB2/SIP1 or Twist [2]. Receptor tyrosine kinase 
(RTK)/Ras and transforming growth factor (TGF)-β signaling as well as Wnt/β-catenin-, 
Notch-, Hedgehog- and NF-κB-dependent pathways can induce and maintain EMT during 
cancer progression [1, 3].  
The pivotal role of EMT in hepatocellular carcinoma (HCC) has been increasingly recognized 
and various molecular mechanisms of hepatocellular EMT have been identified [4, 5]. In 
human HCC, EMT correlates with invasive tumors, intrahepatic metastasis and poor survival 
[6]. This is of particular relevance since intrahepatic metastases were observed in more than 
30% of HCC cases after liver surgery and in 80% of HCC autopsy cases [7].  
Epidemiologically, HCC has a poor prognosis and represent the third most cause of death 
from cancer worldwide due to diagnosis at advanced stages and lack of effective therapy 
options [8]. Thus, HCC therapy is hampered by the fact that the liver is central for xenobiotic 
metabolism resulting in rapid modifications and efflux of drugs. Curative therapies such as 
resection and liver transplantation are applicable in only 15% of HCC patients [9] and show a 
high incidence of recurrence [10]. Unresectable HCC are treated with locoregional therapies 
involving transarterial chemoembolization (TACE), percutaneous ethanol injection or 
radiofrequency ablation [11]. TACE represents an intra-arterial administration of therapeutic 
drugs combined with embolizing agents which leads to a more selective distribution and a 
higher retention time of therapeutics within HCC. TACE has been established as the standard 
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therapy for patients with intermediate stage cancer [12], although the efficacy of TACE is 
limited and patients often suffer from recurrence [13]. The most frequently used 
chemotherapeutics for TACE are doxorubicin, cisplatin and epirubicin, either alone or in 
combination [14], from which doxorubicin or cisplatin showed significant benefits [13]. 
Moreover, targeted therapeutic agents such as the multikinase inhibitor sorafenib has been 
shown to have survival benefits especially in patients with advanced stage HCC [15-17]. 
Those studies are the basis to develop treatment modalities to efficiently combat HCC 
progression that is considered as utmost treatment-resistant. However, suitable human HCC 
models are required to identify potential molecular targets, to test drug efficacy and to 
estimate the effective concentration of therapeutic agents. 
Here, we established a human model of EMT which reflects important aspects of HCC 
progression and allows to study its underlying molecular mechanisms. The matched pair of 
epithelial and mesenchymal HCC cells enables us (i) to evaluate the efficacy of currently used 
therapeutic agents in single or combined treatments and (ii) to assess the effectiveness of 
novel anti-cancer agents during HCC progression. 
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3.3. Material and Methods 
Cell culture 
HCC-1.2 and HCC-1.1 cells, referred to as 3p and 3sp cells, respectively, were isolated from 
one HCC patient as described [18]. 3p cells of passages 10 to 12 and 3sp cells of passages 7 to 
13 are termed 3p early and 3sp early, respectively. 3p cells between passage 71 and 76 and 
3sp from passage 72 to 87 were termed 3p late and 3sp late, respectively. Without particular 
designation of 3p and 3sp cells, passage numbers between 40 and 50 were employed. Details 
are described in Supplementary Material and Methods.  
 
Quantitative Real Time PCR 
PCR reactions were performed with Fast SYBR Green Master Mix (Applied Biosystems, 
Foster city, CA, USA) in duplicates according to the recommendations of the manufacturer 
and quantified with the 7500 Fast Real Time PCR System (Applied Biosystems, CA, USA). 
Arbitrary units were calculated by the dCT method. Forward and reverse primers are 
described in Supplementary Table 1. 
 
Confocal immunofluorescence microscopy  
Cells were seeded onto SuperFrostPlus glass slides (Menzel, Vienna, Austria) and fixed with 
either 4% paraformaldehyde or methanol/aceton. Staining with antibodies and nuclei is 
described in Supplementary Material and Methods.  
 
Proliferation analysis 
1.5 x 104 cells were plated and cell numbers were determined after various time points with a 
multichannel cell analyzer (CASY; Schärfe Systems, Reutlingen, Germany). Three 
independent experiments were performed in triplicates. 
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Cell migration and invasion assays 
Cell migration and cell invasion was determined by Platypus Technology according to the 
manufacturer’s protocol (Oris™ Cell Invasion & Detection Assay, Madison, USA). To 
analyze cell migration, 5 x 104 cells were plated onto 8 not-coated wells. To examine cell 
invasion, same cell numbers were seeded into 8 basal membrane extract (BME; 3.5mg/ml)-
coated wells and overlaid with undiluted BME. Migration and invasion of cells was 
microscopically analyzed and quantitatively evaluated by measuring the fluorescence after 
staining with CellTracker™ (Green CMFDA; Invitrogen, Carlsbad, USA). 
 
Comparative genomic hybridization (CGH)  
Genomic DNA was isolated from early and late 3p and 3sp HCC cells using the QIAamp 
DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol. CGH 
analysis was performed using human 4x44K whole genome oligonucleotide-based arrays 
(Agilent, Santa Clara, USA). Details are described in Supplementary Material and Methods.  
 
Expression profiling using microarrays 
Total RNA was isolated from duplicates of early and late 3p and 3sp HCC cells using the 
RNAeasy kit (Qiagen, Hilden, Germany). The integrity and quantity of RNA was analyzed by 
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, USA). cRNA labeling and 
hybridization on Affymetrix GeneChip® Human gene 1.0 ST Array (Affymetrix, Santa Clara, 
USA) as well as scanning of signal intensities was performed according to the manufacturer’s 
protocol. The ratio of regulation was calculated and a minimum of 3-fold regulation was 
considered as significant. Computational analysis was performed with Gene set enrichment 
analysis (GSEA) software (http://www.broad.mit.edu/gsea/msigdb/annotate.jsp) by 
comparing the molecular profile data with existing as well as self-defined gene sets. 
 
Diploma thesis ‘Drug Assessment during EMT of HCC’  Sabine Mall 
   
 
 40  
Analysis of CpG methylation 
Genomic DNA was isolated from 3p and 3sp HCC cells grown in quadruplicates and from 
primary peripheral blood cells using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany). The digestion of 600 ng genomic DNA with methylation-sensitive restriction 
enzymes (MSRE) was performed. In total, 327 cancer-specific promoter loci were analyzed 
by PCR. Detailed procedure is described in Supplementary Material and Methods. 
 
Therapeutic agents 
Doxorubicin hydrochloride (adriamycin hydrochloride), cis-Diammineplatinum (II) dichloride 
(cisplatin) and epirubicin hydrochloride were purchased from Sigma, St Louis, USA and 
dissolved in 0,9% NaCl. Sorafenib (Nexavar®; Bayer HealthCare Pharmaceuticals, Wayne, 
USA), Erlotinib (Tarceva®; LC Laboratories, Woburn, USA) and Bevacizumab (Avastin®; 
Roche, Basel, Switzerland) were dissolved in dimethylsulfoxide (DMSO). Stock solutions 
were diluted in medium to concentrations indicated in the text. 
  
Determination of the inhibitory concentration (IC)50  
Cell viability was determined using the 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Briefly, cells were seeded in triplicates at a density of 6 x 103 cells per 
well. After 24 hours, cells were incubated with drug-containing medium for three days. Cells 
were incubated with MTT solution (5mg/ml; Sigma, St Louis, USA) and after five hours 
medium was replaced with DMSO. The absorbance was measured at 620 nm by employing a 
microplate reader (Asys HiTech, Salzburg, Austria). MTT assays were repeated 3 times for 
each drug application and untreated cells were used as reference. IC50 values were obtained by 
log-linear interpolation of data points and are depicted by dose-response curves using the 
software GraphPad Prism® 5.01. 
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Statistical analysis 
Data are expressed as means ± standard deviation (SD). The statistical significance of 
differences was evaluated using an unpaired, non-parametric Student’s t-test. Significant 
differences between experimental groups were * p<0,05, ** p<0,01 or *** p<0,005. 
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3.4. Results 
HCC cells show an epithelial phenotype and a mesenchymal one correlating with enhanced 
cell motility.  
Two distinct liver cell lines were isolated from the HCC of one patient [18]. Phase contrast 
analysis suggested an epithelial cell type, termed 3p, and a mesenchymal cell population, 
designated 3sp (Fig. 1A). Both HCC cells showed diploid DNA content (Supplementary Fig. 
1) and short tandem repeat analysis verified their common genomic identity (Supplementary 
Table 2). qRT-PCR analysis revealed that 3p cells express epithelial markers such as E-
cadherin and keratin 8, whereas 3sp cells showed a mesenchymal expression signature by 
upregulation of the transcription factors LEF1, SNAI1, SNAI2 and ZEB1 (Fig. 1B). 
Immunolocalization demonstrated intact adherence junctions by expression of E-cadherin, β-
catenin and p120catenin at cell borders of 3p cells, whereas 3sp cells failed to show this 
phenotype (Fig. 1C). In contrast to 3sp, 3p cells displayed cytoplasmic distribution of the 
epithelial marker keratin 8 by the concomitant absence of the mesenchymal interfilament 
component vimentin. In addition, mesenchymal 3sp cells showed relocalization of actin from 
the cell membrane to stress fibers suggesting enhanced motility.  
We next assessed the migratory and invasive potential of 3p and 3sp cells. First, we 
performed proliferation kinetics to exclude an influence of differential cell doubling rates on 
migration and invasion assays. No significant difference in proliferation of 3p and 3sp cells 
could be detected (Fig. 2A). Yet, a 4-fold increased migratory potential of mesenchymal 3sp 
cells was determined when compared to 3p cells (Fig. 2B and 2C). To analyze invasion, HCC 
cells were embedded into matrigel. While epithelial 3p cells showed no invasive potential, 
mesenchymal 3sp cells displayed a more than 5-fold stronger ability to invade into the matrix 
(Fig. 2D and 2E). The invasive potential of mesenchymal 3sp cells was further analyzed by 3-
dimensional (3D) spheroid formation in collagen gels [19]. Epithelial 3p cells formed 
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compact and round spheroids without cell invasion into the surrounding gel (Supplementary 
Fig. 2A), even though proliferation was not impaired (data not shown). On the contrary, 
mesenchymal 3sp cells failed to form spheroids on their own, however, these cells attached 
onto the surface of epithelial 3p-spheroids after co-cultivation, and showed strong invasion 
into the surrounding matrix (Supplementary Fig. 2A and 2B). Immunofluorescence analysis 
of E-cadherin and β-catenin indicated epithelial characteristics of 3p-derived spheroids, 
whereas these markers could not be detected in invading 3sp cells due to disassembly of 
epithelial junctions (Supplementary Fig. 2C). Taken together, 3p and 3sp cells showed a 
distinct epithelial and mesenchymal phenotype correlating with poor and strong migratory and 
invasive abilities, respectively. 
 
Mesenchymal HCC cells developed through EMT in vivo.  
We further investigated whether 3sp cells have been derived from 3p cells through EMT in 
the HCC patient. CGH analysis revealed a loss of genomic DNA in the TRPM3 and AXIN1 
loci of both cell types (Fig. 3A and 3B). PCR analysis of multiple exons could identify the 
exact chromosomal breaks which are located between exon 12 and 15 and between exon 2 
and 3 in TRPM3 and AXIN1, respectively (Supplementary Fig. 3). This homozygous loss of 
chromosomal regions indicates an identical cellular origin of 3p and 3sp hepatoma cells, and 
thus demonstrates that 3sp cells have been developed from 3p cells via EMT in vivo.  
 To verify EMT, we analyzed the 3p/3sp HCC cell lines by whole-genome expression 
profiling (Fig. 4A and 4B). Remarkably, a large cluster of liver-specific genes were 
downregulated in 3sp cells compared to 3p cells (Supplementary Fig. 4), including CYP450 
phase I enzymes, alcoholdehydrogenase (ADH) and aldehydedehydrogenase (ALDH) and 
phase II enzymes such as UDP-glucuronosyl-transferases (UGT) and glutathione-S-tranferase 
(GST). Importantly, a cluster of epithelial markers involving components of tight junctions 
(claudins), desmosomes (desmoplakin) and adherence junctions (E-cadherin) were found to 
Diploma thesis ‘Drug Assessment during EMT of HCC’  Sabine Mall 
   
 
 44  
be strongly downregulated in mesenchymal 3sp cells (Fig. 4A). Moreover, EMT-specific 
genes such as vimentin, LEF1 and SNAI2 were highly upregulated in 3sp cells (Fig. 4B), thus 
verifiying the expression analysis shown in Fig. 1B and 1C. In addition, expression profiling 
revealed (i) upregulation of growth factors and matrix metalloproteinases (MMPs) such as 
CTGF, TGF−β2 and MMP2, (ii) upregulation of receptors associated with EMT such as 
platelet-derived growth factor (PDGF)-Rβ and DDR2, and (iii) increase of EMT-associated 
proteins such as fibroblast activation protein, lysyl oxidase, tenascin C and SPARC (secreted 
protein, acidic and rich in cysteine). From these data we concluded that mesenchymal 3sp 
HCC cells were derived from epithelial 3p cells via EMT in vivo.  
 
SPARC activation by CpG demethylation.  
We next addressed the differences in the methylation status of gene promoters in 3p and 3sp 
cells. In order to exclude cell culture effects, genomic DNA of 3p/3sp cells from early as well 
as late passages was analyzed. Most notably, SPARC was identified to be epigenetically 
regulated, in line with a 128-fold upregulation of the transcript (Fig. 4B). Methylation-specific 
PCR of the SPARC promoter revealed a lowered methylation status in both early and late 
passaged mesenchymal 3sp cells (Fig. 4C), which was verified by qRT-PCR analysis showing 
a >30-fold increase of SPARC mRNA in 3sp cells (Fig. 4D). Since the CGH profile of the 
SPARC locus was unaffected, these data provide first evidence that the upregulation of 
SPARC is caused by demethylation during HCC progression. 
 
The 3p/3sp EMT model is suitable for drug testing.  
We next used this human HCC model to assess the efficacy of clinically used anti-cancer 
agents. Dose response relationships and corresponding half maximal inhibitory concentrations 
(IC50) of drugs were determined (Table 1) and verified by viability assays (Supplementary 
Fig. 5A). Chemotherapeutics such as doxorubicin, cisplatin and epirubicin currently used for 
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TACE were compared to targeted therapeutic drugs such as the multikinase inhibitor 
sorafenib, the EGFR-inhibitor eroltinib and the VEGF inhibitor bevacizumab. 3sp cells 
showed a slightly higher susceptibility against chemotherapeutics when compared to 3p cells 
(Fig. 5A-C; Table 1), which is explained by downregulation of multiple drug resistance genes 
in 3sp cells (data not shown). Interestingly, 3sp cells were more resistant to targeted therapies 
including sorafenib and erlotinib (Fig. 5D and 5E; Table 1). Bevacizumab did not show an 
effect on neither of the cells (Fig. 5F, Table 1). The high sensitivity towards erlotinib is in line 
with the higher phosphorylation status of EGFR found in 3p cells (data not shown). Of 
particular interest was the higher resistance of 3sp cells towards sorafenib, as expression 
analysis showed a 10-fold upregulation of PDGFR-β (Fig. 4B). Additional targets of sorafenib 
including VEGFR-1, -2, -3 and RAF kinases were found unaltered between 3p and 3sp cells 
(data not shown). As PDGFR-β is described to play an important role in migration [20], we 
analyzed the migratory potential of 3sp cells upon sorafenib treatment (Supplementary Fig. 
5B and 5C). Interestingly, delivery of sorafenib at the IC50 showed a strong reduction of 
migration, whereas control treatment of doxorubicin at the IC50 did not impair migration. 
Together, these data indicate that sorafenib has a lower cytotoxic potential on 3sp cells, 
however, strongly represses their migratory abilities.  
 In recent clinical efforts, sorafenib and doxorubicin were frequently used in combination 
therapy. Thus, we investigated the effect of the combined treatment of these anti-cancer drugs 
in our model of HCC progression. We therefore treated cells with one drug in increasing 
concentrations, while the second drug was kept constant at its IC50. First, variable amounts of 
doxorubicin were applied in combination with the IC50 of sorafenib on 3p and 3sp cells (Fig. 
6A). Compared to doxorubicin monotherapy, cells showed a drastic susceptibility for the 
combined treatment, leading to a reduction of the IC50 for doxorubicin of 60% and 39% in 3p 
and 3sp cells, respectively (Fig. 6B; Table 1). The vice versa treatment, applying variable 
amounts of sorafenib in combination with the IC50 of doxorubicin (Fig. 6C) showed a similar 
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result, leading to a reduction of the IC50 for sorafenib of 18% and 50% in 3p and 3sp cells, 
respectively (Fig. 6D; Table 1). Most interestingly, we observed a nomalization of the IC50 
values between 3p and 3sp cells after combined treatment in both approaches (Fig. 6B and 
6D, Table 1). Taken together, these results indicate that the monotherapy shows considerable 
differences in the susceptibility between HCC cells undergoing EMT. Our data provide 
evidence that the combined use of doxorubicin and sorafenib is highly efficient to target both 
epithelial and mesenchymal HCC cells. 
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3.5. Discussion 
EMT has been increasingly recognized to play a crucial role in HCC progression by the 
acquisition of invasive properties. In line with the transdifferentiation of neoplastic 
hepatocytes to motile mesenchymal derivatives, HCC is described as a heterogenous tumor at 
advanced stages showing clonal expansion of genetically distinct malignant cell populations. 
Therefore, efficient anti-cancer therapy depends on targeting cancer cells at all stages of 
differentiation.  
EMT has been suggested as the critical step in tumor cell dissemination and particularly 
associates with resistance towards chemotherapy and immunotherapy [1]. Here we established 
and characterized the first human cellular model of EMT in HCC progression allowing us to 
determine drug efficacy of novel and currently approved anti-cancer agents. Our data revealed 
that epithelial cells are more sensitive to the targeted therapeutic agents such as sorafenib and 
erlotinib, whereas mesenchymal cells show a more efficient susceptibility to 
chemotherapeutic drugs such as doxorubicin, cisplatin and epirubicin. Combined application 
of sorafenib and doxorubicin showed two advantages. Firstly, the effective concentration of 
drugs could be reduced and side effects could be minimized. Secondly, combined therapy is 
capable of targeting both, epithelial and mesenchymal cells, which might have the potential to 
reduce the risk of HCC recurrence. Yet, both cell lines showed no response against 
bevacizumab, referring to the limitation of the HCC model to study angiogenic mechanisms 
in vitro. 
The efficacy of combining sorafenib and doxorubicin was shown in a phase II trial, resulting 
in increased overall and progression free survival in patients with advanced HCC compared to 
those who received a monotherapy with doxorubicin [21]. Furthermore, a phase III 
randomized study which compares sorafenib together with or without doxorubicin treatment 
in advanced or metastatic liver cancer is currently recruiting HCC patients 
Diploma thesis ‘Drug Assessment during EMT of HCC’  Sabine Mall 
   
 
 48  
(http://www.clinicaltrial.gov, NCT01015833). Other ongoing clinical trials investigate the 
combination of sorafenib and doxorubicin or other chemotherapeutics using TACE 
(NCT01011010, NCT00478374, NCT0085528).  
Our data revealed a significant upregulation of SPARC in mesenchymal 3sp cells which has 
been reported in patient samples at advanced stages of disease [22]. The role of this protein in 
hepatocarcinogenesis, however, is rather ambiguous by acting either as a tumor promoter [23] 
or tumor suppressor [22]. Notably, we could show for the first time that SPARC is 
epigenetically upregulated in human HCC progression by demethylation. Further studies will 
reveal the consequences of SPARC overexpression in hepatocarcinogenesis. In the same line, 
CGH  analysis revealed homozygous loss of the Wnt signaling component AXIN1 as well as 
of the cation-selective channel TRPM3. While deletion of TRPM3 has not been reported in 
cancer progression, AXIN1 was found to be mutated in 5-25% of HCC patients and 
associated with poor differentiation [24]. These findings show that our EMT model is 
genetically well defined and thus, particularly valid to study human HCC progression without 
unkown genetic variations in widely used human hepatoma cell lines.  
Human models of hepatocellular EMT which reliably reflect HCC progression are invaluable 
tools in pre-clinical studies for (i) the identification of molecular mechanisms underlying 
HCC progression, (ii) the pharmacological determination of dose-effect relationships and thus 
the efficacy of single and combined treatments with novel and currently used therapeutic anti-
cancer drugs, and (iii) the (re)-evaluation of drug target specificity and pleiotropic effects 
after drug application. 
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3.8. Figure legends 
Fig. 1. Epithelial and mesenchymal characteristics of 3p and 3sp HCC cells. (A) Phase 
contrast images display an epithelial (3p) and a fibroblastoid phenotype of 3sp cells (bar, 50 
µm). (B) qRT-PCR analysis of epithelial (E-cadherin, keratin 8) and mesenchymal markers 
(LEF1, SNAI1, SNAI2 and ZEB1) in 3p and 3sp cells. (C) Confocal immunofluorescence 
analysis of the epithelial markers E-cadherin, β-catenin, p120catenin and keratin 8 as well as 
the mesenchymal marker vimentin. Localization of actin at cell membranes and as stress 
fibers as indicated by phalloidin staining (red). Nuclei were counterstained with To-Pro3 
(blue). Bar, 25 µm. dCT, delta CT value. 
 
Fig. 2. Mesenchymal 3sp HCC cells exhibit enhanced migration and invasion. (A) 
Proliferation kinetics of epithelial 3p and mesenchymal 3sp cells. (B) Migration assay using 
the Platypus® technology after 3 days (C) Quantification of cell migration by fluorometric 
analysis. (D) Invasion assays employing the Platypus® technology after 7 days. Upper panel 
and lower panel show the invasion area in the absence and presence of the mask, respectively. 
(E) Quantification of cell invasion by fluorometric analysis. Cells were visualized with green 
CellTracker™. Bar, 250 µm; ***, p<0,005. 
 
Fig. 3. Mesenchymal 3sp HCC cells derived from epithelial 3p HCC cells through EMT 
in vivo. CGH analysis revealed a homozygous loss of genomic DNA in 3p and 3sp cells. (A) 
Homozygous loss of DNA in the TRPM3 and (B) AXIN1 gene locus. Red bars indicate exons 
and blue bars denote the positions of arrayed oligonucleotides on the chromosome. bps, 
basepairs. 
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Fig. 4. Global transcriptome analysis shows regulation of EMT-specific genes in 3sp 
HCC cells. Gene Set Enrichment Analysis of a whole-genome Affymetrix GeneChip® was 
performed. (A) Downregulation (blue) of epithelial markers and (B) upregulation (red) of 
EMT regulators in 3sp cells were determined. The -fold upregulation of mRNA was 
calculated and depicted by the ratio of (A) 3p to 3sp cells (3p/3sp) and of (B) 3sp to 3p cells 
(3sp/3p). (C) DNA methylation testing by qPCR upon methylation-sensitive digestion shows 
demethylation of the SPARC promoter in 3sp cells. 4 replicates of each cell type were 
analyzed. DNA from male (n=4) and female (n=4) blood were used as negative controls. (D) 
Confirmation of SPARC upregulation in 3sp cells by qRT-PCR. dCT, delta CT value. 
ACTA2, smooth muscle actin; CDH1, E-cadherin; CLDN, claudin; CTGF, connective tissue 
growth factor; DDR2, discoid domain receptor; DSP, desmoplakin; EPCAM, epithelial 
cellular adhersion molecule; FAP; fibroblast activation protein; HNF4A, hepatocyte nuclear 
factor 4α; KRT, keratin; LEF1, lymphoid enhancing factor 1; LOX, lysyl oxidase; MMP, 
matrix metalloproteinase; PDGF-Rβ, platelet-derived growth factor receptor β; SNAI2, Slug; 
SPARC, secreted protein, acidic, cystein-rich; TGF-β, transforming growth factor-β; TNC, 
tenascin C; VIM, vimentin. 
 
Fig. 5. Mesenchymal 3sp HCC cells respond to cytostatic agents rather than to targeted 
therapeutic drugs. Cytotoxicity of anti-cancer agents was analyzed by MTT assays and IC50 
values were calculated. Dose-response relationships of 3p and 3sp cells were compared. Red 
dotted lines indicate IC50. 
 
Fig. 6. Combined treatment with sorafenib and doxorubicin efficiently targets both, 
epithelial and mesenchymal HCC cells. Combined application was performed by delivering 
cells with one drug in increasing concentrations while the second drug was kept constant at 
the IC50 concentration. Dose response relationships for 3p and 3sp cells upon (A) treatment 
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with doxorubicin alone or in combination with sorafenib (+ IC50 sora) and (C) sorafenib alone 
or in combination with doxorubicin (+ IC50 doxo) are shown. The resulting change of IC50 
values (arrow, %) of single to combined treatment are depicted for (B) doxorubicin and (D) 
sorafenib. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.9. Figures  
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Figure 3
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Figure 4
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Figure 5 
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Figure 6
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Table 1. IC50 values of anti-cancer agents after single or combined therapeutic  
treatment of 3p and 3sp cells.  
 
n.d. not determined 
 
IC50 [µM] 
chemotherapeutics targeted therapeutic agents 
drug 3p 3sp drug 3p 3sp 
cisplatin 19,01 10,14 erlotinib 14,30 399,23 
epirubicin 9,79 7,66 bevacizumab n.d. n.d. 
doxorubicin 0,98 0,65 sorafenib 9,27 17,54 
doxorubicin 
(+ sorafenib) 0,39 0,39 
sorafenib 
(+ doxorubicin) 7,63 8,83 
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3.10. Supplementary Material 
Supplementary Material and Methods 
Cell Culture  
Human 3p and 3sp heptoma cells were cultured on plastic in RPMI supplemented with 10% 
fetal calf serum (FCS) and antibiotics, except that early 3p cells were grown on collagen-
coated tissue culture plates in ACL-4 medium supplemented with 5% FCS. All cells were 
kept at 5% CO2 and 37°C and routinely screened for the absence of mycoplasma, 
 
Analysis of diploidy 
Cells were trypsinized, washed with PBS and 1 x 106 cells were incubated with 1 ml 
hypotonic DNA staining buffer containing 5mg/ml propidium iodide (Calbiochem, San 
Diego, CA, USA), 0,1% sodium citrate, 0,3% Triton X-100 and 20 µg/ml ribonuclease A (all 
from Sigma, St. Louis, MO, USA) for 30 minutes on 4°C in the dark. Determination of the 
DNA content was performed by flow cytometry (FACSCalibur, BD Biosciences, San Jose, 
CA, USA) 
 
Short tandem repeat (STR) analysis 
PCR of seven short tandem repeats (Supplementary Table 1) was performed to verify the 
genetic origin of human 3p and 3sp hepatoma cells. 
 
3-dimensional (3D) spheroid formation of HCC cells 
Spheroid formation and incubation was performed as described [1]. Briefly, a cell suspension 
of 3 x 102 3p cells per 100 µl or a 1:1 mixture of 3p and 3sp cells in RPMI containing 20% 
methyl cellulose (Sigma, St Louis, MO, USA) was incubated for 3 days at 37°C and 5% CO2. 
After harvesting, 96 spheroids were mounted in collagen I (Sigma, St Louis, MO USA) and 
Diploma thesis ‘Drug Assessment during EMT of HCC’  Sabine Mall 
   
 
 64  
plated into flexiPERM conA wells (Greiner Bio-One GmbH, Kremsmuenster, Austria) to 
harden at 37°C for 15 minutes. Gels were then transferred into a 24-well plate and incubated 
with medium at cell culture conditions as outlined. CellTracker™ (Green CMFDA; 
Invitrogen, Carlsbad, USA) was applied at a concentration of 5 µM before spheroid formation 
and incubated as outlined by the instructions of the manufacturer (Invitrogen, Eugene, 
Oregon, USA). The fluorescence signal was visualized by microscopy (Nikon, TE 300, 
Japan). 
 
Confocal immunofluorescence microscopy of spheroids 
Collagen gels were fixed in 4% formaldehyde/PBS for 10 minutes at room temperature. After 
blocking for 30 minutes (1% PBS/0.5% Tween 20/0.2% fish gelatine with 0.2 mg/ml IgG1) at 
room temperature, the following primary antibodies were applied at a dilution of 1:100: anti-
β-catenin (BD Transduction Laboratories, Lexington, UK), anti-E-cadherin (BD), anti-
p120catenin (p120ctn; BD)), anti-keratin 8 (Progen, Heidelberg, Germany), Texas Red-X 
phalloidin (Invitrogen, Carlsbad, USA) and anti-vimentin (Sigma, Saint Louis, USA). The 
corresponding secondary antibody (Alexa 488; Invitrogen, Carlsbad, USA) was applied after 
one hour. Nuclei were visualized with To-Pro3 (Invitrogen, Carlsbad, USA) at a dilution of 
1:10.000. Imaging was performed by confocal immunofluorescence microscopy (Zeiss, Jena, 
Germany). 
 
Polymerase chain reaction (PCR) of genomic DNA 
Chromosomal DNA was isolated with GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma; St Louis, MO, USA). PCR was performed using chromosomal DNA and illustra 
PuReTaq Ready-To-Go PCR beads (GE Healthcare, Buckinghamshire, UK) and 4 µM primer 
mix of following primers: human TRPM3: exon 1, forward (for) 5’-
CAGGCAAGGCTACTTGACTA-3’, reverse (rev) 5’-CACCAGCCTCTTGTCTCTGA-3’; 
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exon 3, for 5’-GGTGGACGGAGAAGGGCAGGA-3’, rev 5’-
GGGGCAGGGGACTCAGAGCA-3’; exon 6, for 5’-CTCCTAGCTCCCCGCCACCA-3’, 
rev 5’-TGCCAGTGGGAACAACCGCT-3’; exon 8, for 5’-
TCCACAATTAGACATGACGCTGCAA-3’, rev 5’-GCTGGCCACCCATGCGGAAT-3’; 
exon 9, for 5’-CCTGACTCATAGCAAGGGCCCCA-3’, rev 5’-
GCTGTCAGGATAGCCAAATCAATGTCC-3’; exon 10, for 5’-
ATGCCTCGGCCCCAGACCAA-3’, rev 5’-AGATGGCGCCTGCAGAGGGA-3’; exon 12, 
for 5’-TGAACTGCCCTCCACCAGCCA-3’, rev 5’-GGTCAGTCAGGCAGCTCCCCA-3’; 
exon 15, for 5’-AGGACAGGAGCTGGCCTCGT-3’, rev 5’-
CCTGTGTGTGCATCACTGGGGT-3’; exon 18, for 5’-GCCTGGCCTTCCCAGGCTAC-3’, 
rev 5’-TGGACGTTGGCTCCTTGTGGC-3’; exon 21, for 5’-
TCCCTCTGCTTCCCCACCCT-3’, rev 5’-TCAACACATGGCCCTGGGAGT-3’; exon 24, 
for 5’-TCTCTGCCACACCCCCAGCC-3’, rev 5’-TCTGCAGGAGGCAGGTGTCCA-3’; 
exon 25, for 5’-CTCCTGCAGCCCCTGCCAAC-3’, rev 5’-
GGGAAGGCAGCTCTGTCCGC-3’. Human AXIN1: exon 1, for 5’-
CCGGCTACCCGAGATACTCAGCA-3’, rev 5’-GCTCCAGGCATCATGGCAGCAA-3’; 
exon 2, for 5’-CCCCCAGTGCCTGGTGAGGA-3’, rev 5’-TGGGGCTCTCCGAGCCTGTC-
3’; exon 3, for 5’-TCCTGGCGGGAGCCAGTCAA-3’, rev 5’-
CTGCACCAGCGTCGGCAGAA-3’; exon 4, for 5’-ACAGGCAGGCACAAGGAGGC-3’, 
rev 5’-CCCTGCTGCCCTCAGGGACT-3’; exon 5, for 5’-
GGCCGGACACGAAAAGGGGG-3’, rev 5’-CATCAGGACATCCCGGCGGC-3’; exon 6, 
for 5’-CGGCGATCCATCGTCAGGGC-3’, rev 5’-GCGAGGCCATCACTGGCGTT-3’; 
exon 7, for 5’-AGGATGCGGAGAAGAACCAG-3’, rev 5’-
AGAAGTGCTCACGCTACACA-3’; exon 8, for 5’-ACGAGGAAGCCACAGCCCCA-3’, 
rev 5’-TGCCTCCAGGACCTCTGCCC-3’; exon 9, for 5’-AGACCGAGTTGCCACGCACG-
3’, rev 5’-CCGGGAGGACCCTCAGGACG-3’; exon 10, for 5’-
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TGAGGCCAGCAGGAGGGACC-3’, rev 5’-GGGCCGAAAGCCTGATGCCA-3’; exon 11, 
for 5’-GGCCGTCCTGCCCGTCTTTG-3’, rev 5’-GGCTGGAGGCAGGTGCAGTG-3’. 
 
Verification of IC50 values by proliferation 
6 x 104 cells /well were seeded in triplicates on collagen-coated 12-well plates and incubated 
with drugs at a concentration of determined IC50 values for 3 days. Cells were trypsinized and 
counted with a cell counter (CASY, Roche, Basel, Switzerland). Untreated cells were used as 
reference to calculate the percentage of proliferation.  
 
Comparative genomic hybridization (CGH)  
Male reference DNA (Promega, Madison, USA) and sample DNA were digested with AluI 
and RsaI (Promega, Madison, USA) and labeled by random priming with Cyanine 3- and 
Cyanine 5-dUTP (Perkin-Elmer, Massachusetts, USA), respectively, by using the BioPrime 
Array CGH Genomic Labeling Kit (Invitrogen, Carlsbad, USA). After purification with 
Microcon YM-30 filter units (Millipore, Billerica, USA), the two labeled DNA species were 
hybridized together with human cot-DNA (Roche, Basel, Switzerland) onto CGH arrays for 
48 hours at 65°C. Slides were scanned with a G2505B Micro Array Scanner (Agilent, Santa 
Clara, USA). Feature extraction and data analysis were performed using the Feature 
Extraction and DNA Analytics software (Agilent, Santa Clara, USA), respectively.  
 
Analysis of CpG methylation 
600 ng genomic DNA of 3p and 3sp HCC cells and from pimary peripheral blood cells were 
digested with methylation-sensitive restriction enzymes (MSRE) overnight at 37°C by 
employing a mixture of 6 units of each AciI (New England Biolabs, Frankfurt am Main, 
Germany), Hin6I (Fermentas, St. Leon-Rot, Germany) and HpaII (Fermentas). Quantitative 
polymerase chain reaction (qPCR) was performed on MSRE-digested DNA covering the CpG 
Diploma thesis ‘Drug Assessment during EMT of HCC’  Sabine Mall 
   
 
 67  
rich area at chr5:151,066,289-151,066,501 (human genome annotation: hg 19), including part 
of the first gene coding exon. This sequence region contains 9 MSRE sites when using the 
mixture of 3 enzymes mentioned above. Completion of digestion was confirmed using a 
control PCR covering known differentially methylated regions (DMRs; H19, IGF2, ABL1, 
PITX2, XIST and FMR1) as published recently [2]. 10 ng of MSRE-digested DNA was 
amplified in 10 µl PCR volume using 0.3 U HotStarTaq polymerase and buffer containing 1.5 
mM MgCl2 (Qiagen, Hilden, Germany) using a 384-well format and the LightCycler® LC480 
(Roche, Vienna, Austria). Cycling was performed with 15 minutes of initial denaturation 
followed by 50 cycles with each 95°C for 40 sec, 65°C for 40 sec and 72°C for 80 sec 
including a final extension at 72°C for 7 minutes. A melting curve analysis was performed for 
confirming specificity of amplicons with a Tm of 88.4°C ±0.6°C. Cp values were extracted 
from qPCR-data using the LigthCycler LC480 software. Boxplots were generated from 
quadruplicate “45-Cp” values using R statistical software. 
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Supplementary Figure legends 
Supplementary Fig. 1. Human 3p and 3sp hepatoma cells are diploid. Flow cytometry 
analysis of cells stained with propidium iodide indicates diploid DNA content of (A) early 
and (B) late 3p cells as well as (C) early and (D) late 3sp cells.  
 
Supplementary Fig. 2. Cell invasion of mesenchymal 3sp cells in 3-dimensional (3D) co-
cultured 3p/3sp-derived spheroids. (A) 3p cells form compact and round spheroids which 
are unable to invade into the surrounding collagen gel. Co-cultivation of epithelial 3p and 
mesenchymal 3sp cells (3p + 3sp) showed spheroid formation and strong invasion into the gel 
(bar, 250 µm). (B) Staining of co-cultivated spheroids with CellTracker™ revealed that only 
mesenchymal 3sp cells (green) invade into the gel, while epithelial 3p cells (red) reside in the 
center of the spheroid (bar, 250 µm). (C) Immunofluorescence staining of membrane-bound 
β-catenin and E-cadherin showing the epithelial organization of 3p cells in a 3D setting, while 
detached mesenchymal 3sp cells (white arrows) from a co-cultivated spheroid lose these 
epithelial markers (bar, 25 µm). 
 
Supplementary Fig. 3. Identification of chromosomal break points in TRPM3 and 
AXIN1. PCR discloses chromosomal breaks of (A) TRPM3 between exon 12 and exon 15 
and of (B) AXIN1 between exon 2 and exon 3 in 3p and 3sp cells. Genomic DNA of primary 
human hepatocytes (prim hep) were used as control. Ex, exon; bp, 100 basepair ladder. 
 
Supplementary Fig. 4. Downregulation of liver specific genes in 3sp HCC cells. Gene Set 
Enrichment Analysis (GSEA) of a whole-genome Affymetrix GeneChip® revealed 
downregulation of liver-specific genes in 3sp cells. Blue and red indicates down- and 
upregulation, respectively. 
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Supplementary Fig. 5. Sorafenib efficiently blocks cell migration of mesenchymal 3sp 
HCC cells. (A) Verification of calculated IC50s by viability assays. Incubation of 3p and 3sp 
cells with drugs at their determined IC50 results in a reduction of viable cells to 50%. (B) 
Migration assays using the Platypus® technology shows movement of mesenchymal 3sp cells 
into the detection zone after 3 days. Treatment of doxorubicin at the IC50 shows a reduction of 
the cell number but no impaired migration, whereas treatment of sorafenib at the IC50 leads to 
a significantly reduced migratory potential of 3sp cells. (C) Quantification of 3sp cell 
migration by fluorometric analysis. Cells were visualized with green CellTracker™. Bar, 250 
µm; ***, p<0,005. 
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Supplementary Figure 4 
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Supplementary Figure 5 
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Supplementary Table 1. Primer for quantitative Real Time PCR 
gene forward primer reverse primer 
RhoA CCATCATCCTGGTTGGGAAT CCATGTACCCAAAAGCGC  
E-cadherin ACCACCTCCACAGCCACCGT GCCCACGCCAAAGTCCTCGG 
K8 AGGAGGCCGCTATGCAGGGT GCTGGAGGCATGGGCAAGGG 
LEF1 ACCCCACCTCTTGGCTGGCA TGTGGGGACCAGGAGGACCG 
SNAI1 GGCCCACCTCCAGACCCACT CTCGAGGGTCAGCGGGGACA 
SNAI2 GTCCGTCTGCCGCACCTGAG CAGGAAGGAGCGCGGCATCT 
ZEB1 CGTGGCCATTGCTGACCAGA TTGGACTGCAGGGCTGACCG 
ZEB2 GCCGAGTCCATGCGAACT AATGAAGCAGCCGATCATGG 
 
Abbreviation: Keratin 8, Lymphoid enhancer binding factor (LEF)1, Snail (SNAI1), Slug (SNAI2), Zinc finger 
E-box binding homeobox (ZEB)1 and 2. 
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Supplementary Table 2. Short tandem repeat analysis of 3p and 3sp HCC cells. 
3p 3sp marker location primer pair 
338,346 338,346 CSF1PO 5q33.1 CCGGAGGTAAAGGTGTCTTAAAGT ATTTCCTGTGTCAGACCCTGTT 
198,000 198,000 D13S317 13q.31.1 ATTACAGAAGTCTGGGATGTGGAGGA GGCAGCCCAAAAAGACAGA 
152,000 152,000 vWA 12p13.31 GCCCTAGTGGATGATAAGAATAATCAGTATGTG GGACAGATGATAAATACATAGGATGGATGG 
223,230 223,230 D7S820 7q.21.11 ATGTTGGTCAGGCTGACTATG GATTCCACATTTATCCTCATTGAC 
270,274 271,000 TPOX 2p25.3 GCACAGAACAGGCACTTAGG CGCTCAAACGTGAGGTTG 
130,142 130,142 D5S818 5q23.2 GGTGATTTTCCTCTTTGGTATCC AGCCACAGTTTACAACATTTGTATCT 
282,000 282,000 D16S539 16q24.1 GGGGGTCTAAGAGCTTGTAAAAAG GTTTGTGTGTGCATCTGTAAGCATGTATC 
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4. Abbreviations 
α-SMA alpha smooth muscle actin 
Akt  V-Akt murine thymoma viral  oncogen homolog 
ARHGEF9 Rho guanine nucleotide exchange factor 9  
AXIN1 Axis inhibitor 1 
BCLC  Barcelona Clinic Liver Cancer Classification 
bHLH   basic helix loop helix  
CCDN1 cyclin D1 
Cdc42  cell division cycle 42 
CDH1  cadherin 1 
CDH1L chromodomain helicase/ATPase DNA binding protein 1 like gene 
CGH  comparative genomic hybridisation 
CLT   cadaveric liver transplantation 
CTGF  connective tissue growth factor 
DEB   drug eluting beads 
DNA  deoxyribonucleic acid 
ECOG  Eastern Cooperative Oncology Group 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor  
EIF5A2 eukaryotic initiation factor 5A2 
EMT  epithelial to mesenchymal transition 
ErbB  avian erythoblastic leukemia viral oncogene homolog 
Erk  extracellular signal regulated kinase 
FOXC2 forkhead box C2 
FSP-1  fibroblast-specific protein 1 
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HBV  Hepatitis B Virus 
HCC  hepatocellular carcinoma 
HCV   hepatitis C virus 
HGF  hepatocyte growth factor 
IC50  half maximal inhibitory concentration 
IFN  interferon 
IGF  insulin-like growth factor 
IGF1-R insulin like growth factor 1 receptor 
LDLT   living donor liver transplantation 
LEF  lymphoid enhancer binding factor  
Ln-5  Laminin – 5 
MAPK  mitogen activated protein kinase 
Mdm2  mouse double minute 2 homolog 
MET   mesenchymal to epithelial transition 
Met  oncogene Met 
miRNA micro ribonucleic acid 
mTOR  mammalian target of Rapamycin 
MUC1  mucin 1, cell surface associated 
p14ARF  cyclin-dependent kinase inhibitor 2A 
PAR6A partitioning defective protein 6  
PCR  polymerase chain reaction 
PDGFR plateled-derived growth factor receptor 
PEI  percutaneous ethanol injection 
PI3K  phoshoinositide 3 Kinase 
PTEN  phosphatase and tensin homolog 
Raf  v-Raf 1 murine leukemia viral oncogene homolog 
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Ras  rat sarcoma viral oncogene 
Rb  Retinoblastoma  
RCTs  randomized controlled trials 
RF  radiofrequency ablation 
RhoB  Ras homolog gene family B 
RPS6  ribosomal protein S6 
SIP1  survival of motor neuron protein interacting protein 1 
siRNA  small interfering ribonucleic acid 
Smad  Mothers against Decapentaplegic 
snRNA small nucleolar ribonucleic acid 
SPARC secreted protein, acidic, rich in cystein 
STAT1 signal transducer and activator of transcription 1 
STR  short tandem repeats 
TACE  transarterial chemoembolization 
TAE  transarterial embolization 
TGF-β  transforming growth factor – β 
TGFβRI transforming growth factor receptor I 
TNM  Tumor – Node – Metastasis classification 
UICC  International Union against Cancer 
VEGFR vascular endothelial growth factor receptor  
Wnt   Wingless type MMTV integration type family 
ZEB  zinc finger E-box binding homeobox 
ZIP1  Smad interacting protein 
ZO-1  zonula occludens – 1 
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